A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

2025-521438-27-00 · tracked via the Priya Life Science EU tracker

Sponsor

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Sponsor type

Pharmaceutical company, Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

19/02/2026

Enrollment target

Sites

Sweden, France, Spain, Germany

Condition studied

advanced, unresectable and/or metastatic solid tumors

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521438-27-00 on CTIS ↗ ← All trials in the EU